USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Avi Biopharma, Inc.
Address:
Avi Biopharma, Inc.
4575 Sw Research Way, Ste 200
Corvallis, OR 97333 0106
Phone:
(541) 753-3635
URL:
N/A
EIN:
930797222
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $920,111.00 5
STTR Phase I $262,849.00 3
STTR Phase II $424,266.00 1

Award List:

THERAPEUTIC APPLICATIONS OF PERFLUOROCARBON MICROBUBBLES

Award Year / Program / Phase:
1998 / STTR / Phase I
Award Amount:
$98,771.00
Agency:
HHS
Principal Investigator:
Iversen
Research Institution:
University of Nebraska
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / STTR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Iversen
Research Institution:
University of Nebraska
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$98,415.00
Agency:
HHS
Principal Investigator:
Patrick L. Iversen
Abstract:
N/a

Inhibition of Androgen Receptor to treat Prostate Cancer

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$250,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Prostate cancer is the second leading cause of cancer death in US men. Prostate cancer is highly dependent on androgen stimulation mediated through the androgen receptor (AR) for growth and proliferation. For those with advanced PCa, androgen ablation remains… More

Antisense Morpholino Oligomers to Treat Retinopathy

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The broad, long-term objectives of the application are to develop antisense inhibitors of retinopathy and document their mechanism(s) of action. Retinopathy is a significant cause of eye disease and has a major impact on development, learning, communicating,… More

Morpholino Antisense Drugs for Hepatitis C Virus

Award Year / Program / Phase:
2004 / STTR / Phase I
Award Amount:
$164,078.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Hepatitis C Virus (HCV) causes a persistent infection in most humans exposed to the virus. HCV infection in time can lead to cirrhosis and hepatocellular carcinoma. Although the annual number of newly infected patients has dropped significantly over the past… More

Apoptotic Regulation of Lymphocyte Responses

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$107,000.00
Agency:
HHS
Principal Investigator:
Dan V. Mourich
Abstract:
DESCRIPTION (provided by applicant): The response of lymphocytes to antigen stimulation is characterized by proliferation of an antigen-sensitive lymphocyte population, subsequent differentiation to subsets with effector cell function, and ultimately the retention of antigen-responsive lymphocytes… More

Antisense Antiviral Agent for West Nile Infections

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$364,696.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): AVI BioPharma has been developing an antisense phosphorodiamidate morpholino oligomer, AVI-4020 for the treatment of West Nile Virus. AVI-4020 has been shown both to reduce viral titer, and to cross the blood brain barrier. This compound targets the translation… More